Clinicopathologic presentations of dermatomycoses in cancer patients

Journal of the European Academy of Dermatology and Venereology

Volumn 22, Issue 8, 2008, Pages 907-917

  Quatresooz, P ^a   Pierard Franchimont C ^a   Arrese, J E ^a   Pierard G E ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Cancer; Dermatomycosis; Dermatophyte; Mold; Yeast

Indexed keywords

BACTERIAL COLONIZATION; BACTERIUM IDENTIFICATION; CANCER PATIENT; CANCER RISK; CANDIDA; CARCINOMA; CELL CULTURE; CLINICAL FEATURE; DERMATOMYCOSIS; DISEASE CLASSIFICATION; EPIDERMOPHYTON; FUNGEMIA; HISTOPATHOLOGY; HUMAN; IMMUNOCOMPROMISED PATIENT; LABORATORY DIAGNOSIS; MICROSPORUM; MOLECULAR BIOLOGY; MOULD; MUCOSAL SQUAMOUS CELL CARCINOMA; MYCOSIS; NEUTROPENIA; NON INVASIVE MEASUREMENT; PRIORITY JOURNAL; REVIEW; SKIN DISEASE; TRICHOPHYTON; YEAST CELL;

ANTIFUNGAL AGENTS; BIOPSY; DERMATOMYCOSES; DIAGNOSIS, DIFFERENTIAL; HUMANS; IMMUNOCOMPROMISED HOST; NEOPLASMS; RISK FACTORS;

EID: 52249110654     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2008.02774.x     Document Type: Review

References (59)

1. Brown AE. Overview of fungal infections in cancer patients. Semin Oncol 1990 17 : 2 5.
2. Walsh TJ, De Pauw B, Anaissie E, Martino P. Recent advances in the epidemiology, prevention and treatment of invasive fungal infections in neutropenic patients. J Med Vet Mycol 1994 32 : S33 S51.
3. Quatresooz P, Arrese JE, Piérard GE. Synopsis des dermatomycoses invasives chez l'immunodéprimé. Rev Med Liège 2003 58 : 690 694.
4. Mays SR, Bogle MA, Bodey GP. Cutaneous fungal infections in the oncology patient. Recognition and management. Am J Clin Dermatol 2006 7 : 31 43.
5. Nosari A, Oreste P, Cairoli R et al. Invasive aspergillosis in haematological malignancies: clinical findings and management for intensive chemotherapy completion. Am J Hematol 2001 68 : 231 236.
6. Piérard GE, Arrese JE, Piérard-Franchimont C, Quatresooz P. Onychomycosis in older patients. Aging Health 2006 2 : 865 870.
7. Piérard GE, Piérard-Franchimont C. The nail under fungal siege in patients with type II diabetes mellitus. Mycoses 2005 48 : 339 342.
8. Piérard-Franchimont C, Arrese JE, Hermanns-Lê T, Piérard GE. Epidemiology of onychomycosis assessed by histomycology in psoriatic patients. J Mycol Med 2006 16 : 159 162.
9. Roeder A, Kirschning CJ, Rupec RA, Schaller M, Weindl G, Korting HC. Toll-like receptors as key mediators in innate antifungal immunity. Med Mycol 2004 42 : 485 498.
10. Tanaka S, Summerbell RC, Tsuboi R et al. Advances in dermatophytes and dermatophytosis. J Med Vet Mycol 1992 30 : S29 S39.
11. Tsuboi R, Ogawa H, Bramano K et al. Pathogenesis of superficial mycoses. J Med Vet Mycol 1994 32 : S91 S104.
12. Piérard GE, Quatresooz P, Arrese JE. Spotlight on nail histomycology. Dermatol Clin 2006 24 : 371 374.
13. Nir-Paz R, Elinay H, Piérard GE et al. Deep infection by Trichophyton rubrum in an immunocompromised patient. J Clin Microbiol 2003 41 : 5298 5301.
14. Aljabre SHM, Richardson MD, Scott EM, Shankland GS. Dormancy of Trichophyton mentagrophytes arthroconidia. J Med Vet Mycol 1992 30 : 409 412.
15. Arrese JE, Piérard GE. Treatment failures and relapses in onychomycosis: a stubborn clinical problem. Dermatology 2003 207 : 255 260.
16. Piérard GE, Piérard-Franchimont C, Arrese JE. The boosted oral antifungal treatment for onychomycosis beyond the regular itraconazole pulse dosing regimen. Dermatology 2000 200 : 185 187.
17. Piérard GE, Piérard-Franchimont C, Arrese JE. The boosted antifungal topical treatment (BATT) for onychomycosis. Med Mycol 2000 38 : 391 392.
18. Piérard GE. Spores, sporodochia and fomites in onychomycosis. Dermatology, 2006 213 : 169 172.
19. Piérard-Franchimont C, Piérard GE. Skin surface strippings in diagnosing and monitoring inflammatory, xerotic and neoplastic diseases. Ped Dermatol 1985 2 : 180 184.
20. Samdani AJ, Dykes PJ, Marks R. The effect of dermatophyte species and density of infection on the pathology of ringworm. J Med Vet Mycol 1991 29 : 279 281.
21. Guého E, Faergemann J, Lyman C, Anaissie EJ. Malassezia and Trichosporon: two emerging pathogenic basidiomycetous yeast-like fungi. J Med Vet Mycol 1994 32 : S367 S378.
22. Chakrabarti A, Marhawa RK, Mondal R et al. Generalized lymphadenopathy caused by Trichosporon asahii in a patient with Job's syndrome. Med Mycol 2002 40 : 83 86.
23. Gupta AK, Bluhm R. Seborrheic dermatitis. J Eur Acad Dermatol Venereol 2004 18 : 13 16.
24. Piérard GE, Xhauflaire-Uhoda E, Piérard-Franchimont C. The key role of corneocytes in pityrosporoses. Dermatology 2006 212 : 23 26.
25. Piérard-Franchimont C, Xhauflaire-Uhoda E, Piérard GE. Revisiting dandruff. Int J Cosmet Sci 2006 28 : 311 318.
26. Piérard GE, Read D, Piérard-Franchimont C, Lother Y, Rurangirwa A, Arresse Estrada J. Cutaneous manifestations in systemic trichosporonosis. Clin Exp Dermatol 1992 17 : 79 82.
27. Piérard GE, Arrese JE, Piérard-Franchimont C, Thiry A, Stynen D. Immunohistochemical expression of galactomannan in the cytoplasm of phagocytic cells during invasive aspergillosis. Am J Clin Pathol 1991 96 : 373 376.
28. Arrese JE, Piérard-Franchimont C, Piérard GE. Fatal hyalohyphomycosis following Fusarium onychomycosis in an immunocompromised patient. Am J Dermatopathol 1996 18 : 196 198.
29. Nucci M, Anaissie E. Cutaneous infections by Fusarium species in healthy and immunocompromised hosts. implications for diagnosis and management. Clin Infect Dis 2002 35 : 909 920.
30. Tosti A, Piraccini BM, Lorenzi S. Onychomycosis caused by nondermatophyte molds: clinical features and response to treatment of 59 cases. J Am Acad Dermatol 2000 42 : 217 224.
31. McCarty JM, Flam MS, Pullen G, Jones R, Kassel SH. Outbreak of primary cutaneous aspergillosis related to intravenous arm boards. J Pediatr 1986 108 : 721 724.
32. Allo MD, Miller J, Townsend T, Tan C. Primary cutaneous aspergillosis associated with Hickman intravenous catheters. N Engl J Med 1987 317 : 1105 1108.
33. Walmsley S, Devi S, King S, Schneider R, Richardson S, Ford-Jones L. Invasive Aspergillus infections in a pediatric hospital; a ten year review. Pediatr Infect Dis J 1993 12 : 673 682.
34. Boutati E, Anaissie E. Fusarium, a significant emerging pathogen in patients with hematologic malignancy. Blood 1997 3 : 999 1008.
35. Abbasi S, Shenep JL, Hughes WT, Flynn PM. Aspergillosis in children with cancer: a 34-year experience. Clin Infect Dis 1999 29 : 1210 1219.
36. Bodey GP, Boktour M, Mays S et al. Skin lesions associated with Fusarium infection. J Am Acad Dermatol 2002 47 : 659 666.
37. Piérard GE, Arrese JE, Quatresooz P. Comparative clinicopathological manifestations of human aspergillosis. A review. Exog Dermatol 2004 3 : 144 153.
38. Piérard GE, Kharfi M, Salomon-Neira MD, Kamoun MR, Piérard-Franchimont C. Itraconazole in human aspergillosis revisited. J Mycol Med 2004 14 : 192 200.
39. Flagothier C, Arrese JE, Quatresooz P, Piérard GE. Cutaneous mucormycosis. J Mycol Med 2006 16 : 77 81.
40. Weitzman I. Saprophytic molds as agents of cutaneous and subcutaneous infection in the immunocompromised host. Arch Dermatol 1986 122 : 1161 1168.
41. Iwen PC, Rupp ME, Hinrichs SH. Invasive mold sinusitis: 17 cases in immunocompromised patients and review of the literature. Clin Infect Dis 1997 24 : 1178 1184.
42. de Shazo RD, O'Brien M, Chapin K, Soto-Aguilar M, Gardner L, Swain R. A new classification and diagnostic criteria for invasive fungal sinusitis. Arch Otolaryngol Head Neck Surg 1997 123 : 1181 1188.
43. Kramer BS, Hernandez AD, Reddick RL, Levine AS. Cutaneous infarction. Manifestation of disseminated mucormycosis. Arch Dermatol 1977 113 : 1076 1076.
44. Rubbin AI, Grossman ME. Bull's-eye cutaneous infarct of zygomycosis: a bedside diagnosis confirmed by touch preparation. J Am Acad Dermatol 2004 51 : 996 1001.
45. Rolston K. Overview of systemic fungal infections. Oncology 2001 15 : S11 S14.
46. Pagano L, Antinori A, Ammassari A et al. Retrospective study of candidemia in patients with hematologic malignancies: clinical features, risk factors and outcome of 76 episodes. Eur J Hematol 1999 63 : 77 85.
47. Grossman ME, Silvers DN, Walther RR. Cutaneous manifestations of disseminated candidiasis. J Am Acad Dermatol 1980 2 : 111 116.
48. Darcis JM, Etienne M, Demonty J, Christophe J, Piérard GE. Candida albicans septicemia with folliculitis in heroin addicts. Am J Dermatopathol 1986 8 : 501 504.
49. Quatresooz P, Meiers I, Arrese J, Boniver J, Piérard GE. Fusariose disséminée chez un patient immunodéprimé. Rev Med Liège 2000 55 : 974 976.
50. Dignani MC, Anaissie E. Human fusariosis. Clin Microbiol Infect 2004 10 : S67 S75.
51. Averbuch D, Boekhout T, Falk R et al. Fungemia in a cancer patient caused by fluconazole-resistant Cryptococcus laurentii. Med Mycol 2002 40 : 479 484.
52. Horré R, Jovanic B, Herff S et al. Wound infection due to Absidia corymbifera and Candida albicans with fatal outcome. Med Mycol 2004 42 : 373 378.
53. Kimura M, Udagawa S, Toyazaki N, Iimori M, Hashimoto S. Isolation of Rhizopus microsporus var. rhizopodifoormis in the ulcer of human gastric carcinoma. J Med Vet Mycol 1995 33 : 137 139.
54. Rubin AI, Baheri B, Scher RK. Six novel antimycotics. Am J Clin Dermatol 2002 3 : 71 81.
55. Koga T, Matsuda T, Matsumoto T, Furue M. Therapeutic approaches to subcutaneous mycoses. Am J Clin Dermatol 2003 4 : 537 543.
56. Gupta AK, Cooper EA, Ryder JE, Nicol KA, Chow M, Chaudhry MM. Optimal management of fungal infections of the skin, hair, and nails. Am J Clin Dermatol 2004 5 : 225 237.
57. Baran R, Gupta AK, Piérard GE. Pharmacotherapy of onychomycosis. Expert Opin Pharmacother 2005 6 : 609 624.
58. Piérard-Franchimont C, Ausma J, Wouters L et al. Activity of the triazole antifungal R126638 as assessed by corneofungimetry. Skin Pharmacol Physiol 2006 19 : 49 56.
59. Piérard GE, Piérard-Franchimont C, Vroome V, Borgers M, Cauwenbergh G. Established and emerging oral antifungals in dermatology. In : Walters KA, Roberts MS, eds. Dermatological and Cosmeceutical Development. Publications Marcel Dekker, New York, forthcoming.